Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase Ia clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
IPO Year: 2020
Exchange: NASDAQ
Website: appliedmt.com
| Date | Price Target | Rating | Analyst |
|---|
15-12G - Applied Molecular Transport Inc. (0001801777) (Filer)
EFFECT - Applied Molecular Transport Inc. (0001801777) (Filer)
POSASR - Applied Molecular Transport Inc. (0001801777) (Filer)
POS AM - Applied Molecular Transport Inc. (0001801777) (Filer)
S-8 POS - Applied Molecular Transport Inc. (0001801777) (Filer)
S-8 POS - Applied Molecular Transport Inc. (0001801777) (Filer)
S-8 POS - Applied Molecular Transport Inc. (0001801777) (Filer)
25-NSE - Applied Molecular Transport Inc. (0001801777) (Subject)
8-K - Applied Molecular Transport Inc. (0001801777) (Filer)
8-K - Applied Molecular Transport Inc. (0001801777) (Filer)
4 - Applied Molecular Transport Inc. (0001801777) (Issuer)
4 - Applied Molecular Transport Inc. (0001801777) (Issuer)
4 - Applied Molecular Transport Inc. (0001801777) (Issuer)
4 - Applied Molecular Transport Inc. (0001801777) (Issuer)
4 - Applied Molecular Transport Inc. (0001801777) (Issuer)
4 - Applied Molecular Transport Inc. (0001801777) (Issuer)
4 - Applied Molecular Transport Inc. (0001801777) (Issuer)
4 - Applied Molecular Transport Inc. (0001801777) (Issuer)
4 - Applied Molecular Transport Inc. (0001801777) (Issuer)
4 - Applied Molecular Transport Inc. (0001801777) (Issuer)
Combined company operating as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) Cash runway extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (NASDAQ:AMTI) ("AMT"), a biopharmaceutical company, announced today the closing of its previously announced transaction pursuant to which AMT will merge with Cyclo Therape
Strong pace of enrollment continues in pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 ("NPC1") Merger with Applied Molecular Transport, Inc. ("AMT") on track to close before year end Company continues to bolster cash position to extend runway through clinical and regulatory milestones Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2023. "Our number one priority remains to
Company Entered into Definitive Merger Agreement with Cyclo Therapeutics Cash and Cash Equivalents of $18.1 million, as of September 30, 2023 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023. Recent Business Highlights and Anticipated Milestones Entered into a definitive merger agreement with Cyclo Therapeutics Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1)The merger is expected to close by year end 20
NEW YORK, Sept. 23, 2023 (GLOBE NEWSWIRE) -- Eastern Bankshares, Inc. (NASDAQ:EBC) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of EBC and Cambridge Bancorp. Under the terms of the proposed transaction, Cambridge Bancorp shareholders will receive 4.956 shares of EBC for each share of Cambridge Bancorp common stock owned. If you are an EBC investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Applied Molecular Transport, Inc. (NASDAQ:AMTI) Lifshi
Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) At closing combined Company will have approximately $13.7 million cash on hand to fund operations into 2H 2024 Upcoming milestones include completion of enrollment in pivotal Phase 3 clinical trial in NPC1, reporting top line data and preparation for NDA submission Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc.
Currently Pursuing Strategic Alternatives, with MTS Health Partners, L.P. Advising the Company Cash and Cash Equivalents of $22.5 million, as of June 30, 2023 SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2023. Financial Results for the Second Quarter Ended June 30, 2023 Research and development (R&D) expenses. Total R&D expenses for the second quarter of 2023 were $2.6 million, compared to $22.8 million for the same period in 2022. The overall decrease was attributable to a restructuring of operations, related reduct
SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2023. Recent Business Highlights Engaged MTS Health Partners, L.P. as advisors in a process to explore strategic alternatives for the companyAppointed Shawn Cross to serve as chief executive officer and board chairTahir Mahmood, Ph.D., co-founder and former CEO remains a member of the board and retained as a consultant Financial Results for the First Quarter Ended March 31, 2023 Research and development (R&D) expenses. Total R&D expenses for the first quarter of 2023 were $
SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company's board of directors approved a workforce reduction of approximately 57% of its employee base and the engagement of MTS Health Partners, L.P. as advisors in a process to explore strategic alternatives for the company. As part of the restructuring, Tahir Mahmood, Ph.D., will leave his post as chief executive officer, but will remain as a board member. Shawn Cross, president and chief operating officer, will now serve as chief executive officer and has been appointed to the board where he will serve
Exploring strategic partnership options to advance AMT-101 for chronic pouchitis, an orphan indication with no FDA-approved products Evaluating next steps for the company's second clinical asset, AMT-126 SOUTH SAN FRANCISCO, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2022. "We were pleased to recently present additional positive AMT-101 translational data at ECCO for our Phase 2 FILLMORE monotherapy trial in patients with chronic pouchitis," said Tahir Mahmood, Ph.D., chi
New positive data demonstrate oral AMT-101's gut-restricted profile with tissue-level pharmacodynamics (PD) effects and no systemic exposure by design Translational analysis reveals IL-10 biological responses in both 3mg and 10mg dose arms SOUTH SAN FRANCISCO, Calif., March 03, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT) today announced additional Phase 2 data for oral AMT-101 in chronic pouchitis patients. AMT-101 is an investigational, once-daily, GI-selective, oral fusion of IL-10 and AMT's proprietary carrier molecule, which is also in development for the treatment of rheumatoid arthritis (RA). AMT presented the data in Poster P584 Efficacy, Safety,
SC 13G/A - Applied Molecular Transport Inc. (0001801777) (Subject)
SC 13D/A - Applied Molecular Transport Inc. (0001801777) (Subject)
SC 13G/A - Applied Molecular Transport Inc. (0001801777) (Subject)
SC 13G/A - Applied Molecular Transport Inc. (0001801777) (Subject)
SC 13G/A - Applied Molecular Transport Inc. (0001801777) (Subject)
SC 13G - Applied Molecular Transport Inc. (0001801777) (Subject)
SC 13G/A - Applied Molecular Transport Inc. (0001801777) (Subject)
SC 13G/A - Applied Molecular Transport Inc. (0001801777) (Subject)
SC 13G - Applied Molecular Transport Inc. (0001801777) (Subject)
SC 13G/A - Applied Molecular Transport Inc. (0001801777) (Subject)
JMP Securities initiated coverage of Applied Molecular with a rating of Outperform and set a new price target of $92.00
JMP Securities initiated coverage of Applied Molecular Transport with a rating of Mkt Outperform and set a new price target of $92.00
SVB Leerink reiterated coverage of Applied Molecular Transport with a rating of Outperform and set a new price target of $74.00 from $32.00 previously
SVB Leerink reiterated coverage of Applied Molecular with a rating of Outperform and set a new price target of $74.00 from $32.00 previously
Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 Three Phase 2 top-line readouts for oral AMT-101 in ulcerative colitis (UC) and rheumatoid arthritis (RA) anticipated in 2022, consistent with previous guidance SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022. "We were pleased to recently announce positive top-line data from our FILLMORE trial in chronic pou
SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Charlene Banard to its Board of Directors. Ms. Banard is an accomplished biopharmaceutical executive with over 30 years of experience leading global technical operations and quality organizations within the life sciences industry. Ms. Banard will also become a member of the company's Audit Committee. "Charlene is a welcome addition to AMT's Board of Directors, bringing critical technical operations expertise and a strong strategic vision to the organization," said Tahir Mahmood, Ph.D.,
Company continues to strengthen key functions and corporate leadership Company on track to announce top-line data from four ongoing oral AMT-101 Phase 2 trials in 2022 SOUTH SAN FRANCISCO, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Carolyn Finkle as senior vice president, head of regulatory affairs. She becomes a member of the AMT executive leadership team, reporting to chief executive officer and co-founder of AMT, Tahir Mahmood, Ph.D. "We are thrilled to welcome Carolyn as the newest member of the executive leadership team at AMT," said Dr. Mahmood. "Car
John W. Smither Appointed to its Board of Directors and Named Audit Committee Chair Graham K. Cooper Named Executive Chair Helen S. Kim Named Lead Independent Director SOUTH SAN FRANCISCO, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of John W. Smither to its Board of Directors and Chair of its Audit Committee. AMT also announced that current Director, Graham K. Cooper, has been named Executive Chair and current Director, Helen S. Kim, has been named Lead Independent Director. "We are delighted to have John join AMT's Board of Directors," said Tahir Mahmood, P
SOUTH SAN FRANCISCO, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Holly Schachner, M.D. a seasoned and accomplished industry veteran to its Board of Directors. "We are very excited to welcome Dr. Schachner to AMT's Board of Directors," said Tahir Mahmood, Ph.D., chief executive officer and co-founder of AMT. "Holly's extensive experience and expertise in late-stage global clinical development and medical affairs across a broad range of therapeutic areas, coupled with her strengths in organizational development, will be invaluable as AMT prepares for the next
Company continues to strengthen key functions of corporate leadership Company on track to announce oral AMT-101 top-line data readouts from the four Phase 2 trials from its comprehensive clinical program beginning in the second half of 2021 Company expanded clinical pipeline with second program, oral AMT-126, and announced first subject dosed in Phase 1a trial in February 2021 SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has appointed Earl Douglas as General Counsel. In his new role, Earl will assume leadership responsibilities for all lega
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has appointed Douglas Rich as Chief Technical Officer. In his new role, Douglas will assume leadership responsibilities for all process development, manufacturing, CMC and formulation activities, including quality and supply chain responsibilities. He will become a member of the AMT Executive Team, reporting to chief executive officer and co-founder of AMT, Tahir Mahmood, Ph.D. “We continue to recognize the criticality of furthering our internal GMP manufacturing and formulation development for the compa
Applied Molecular (NASDAQ:AMTI) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.50) by 66 percent. This is a 73.85 percent increase over losses of $(0.65) per share from the same period last year.
Gainers Plus Therapeutics (NASDAQ:PSTV) shares rose 20.3% to $1.48 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 1.0 million shares, which is 236.3 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $4.2 million. The company's, Q3 earnings came out today. NewAmsterdam Pharma (NASDAQ:NAMS) shares increased by 11.11% to $10.0. The company's market cap stands at $823.2 million. China SXT Pharmaceuticals (NASDAQ:SXTC) shares increased by 10.23% to $2.37. The company's market cap stands at $1.3 million. DarioHealth (NASDAQ:DRIO) stock moved upwards by 7.81% to $1.38. The market value of
-8-K
Gainers American Well (NYSE:AMWL) stock moved upwards by 22.9% to $1.16 during Thursday's after-market session. American Well's trading volume hit 1.3 million shares by close, accounting for 101.4% of its average volume over the last 100 days. The company's market cap stands at $330.2 million. Comera Life Sciences (NASDAQ:CMRA) stock rose 12.73% to $0.3. The market value of their outstanding shares is at $9.2 million. Generation Bio (NASDAQ:GBIO) stock rose 10.83% to $1.33. Trading volume for this security closed at 62.0K, accounting for 38.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $87.6 million. Applied Molecular (NASDAQ
Gainers MicroAlgo Inc. (NASDAQ:MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the performance and efficiency of research institutions. Synaptogenix, Inc. (NASDAQ:SNPX) surged 28.7% to $0.3610. Lifezone Metals Limited (NYSE:LZM) gained 27.4% to $15.29. Lifezone Metals recently reported H1 loss of $16.77 per share. SeqLL Inc. (NASDAQ:SQL) gained 26% to $18.04. Heart Test Laboratories, Inc. (NASDAQ:HSCS) climbed 25.2% to $0.4680. Cemtrex, Inc. (NASDAQ:CETX) rose 21.7% to $6.86. Cheche Group Inc. (NASDAQ:CCG) gained 21.1% to $17.99 amid continued volatility following the company's business combination with Prime Impact Acqu
Gainers Myomo (AMEX:MYO) stock moved upwards by 20.1% to $1.25 during Friday's regular session. Trading volume for Myomo's stock is 192.5K as of 13:30 EST. This is 35.6% of its average full-day volume over the last 100 days. The company's market cap stands at $33.1 million. Cellectar Biosciences (NASDAQ:CLRB) stock rose 18.72% to $2.6. As of 13:30 EST, Cellectar Biosciences's stock is trading at a volume of 168.2K, which is 27.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $25.3 million. Avalo Therapeutics (NASDAQ:AVTX) stock increased by 17.56% to $0.12. The current volume of 282.4 million shares is 996.7% of Avalo Therapeutic
Gainers Avalo Therapeutics (NASDAQ:AVTX) shares rose 38.4% to $0.14 during Friday's pre-market session. The company's market cap stands at $2.8 million. Synaptogenix (NASDAQ:SNPX) stock rose 13.69% to $0.32. The market value of their outstanding shares is at $3.2 million. Hillstream BioPharma (NASDAQ:HILS) stock increased by 13.68% to $0.26. The market value of their outstanding shares is at $4.4 million. SeaStar Medical Holding (NASDAQ:ICU) shares moved upwards by 12.9% to $0.21. The company's market cap stands at $4.0 million. Alpha Teknova (NASDAQ:TKNO) shares increased by 12.23% to $2.11. The market value of their outstanding shares is at $85.9 million. Agile Therapeutics (NASDAQ:A
Gainers GSE Systems, Inc. (NASDAQ:GVP) shares rose 32.4% to $0.4090 in pre-market trading after falling over 3% on Thursday. Roadzen (NASDAQ:RDZN) shares rose 23.4% to $8.11 in pre-market trading after falling more than 40% on Thursday. FLJ Group Limited (NASDAQ:FLJ) shares gained 20.3% to $0.3669 in pre-market trading. Blue Star Foods Corp. (NASDAQ:BSFC) shares rose 17.1% to $0.37 in pre-market trading. Blue Star Foods recently announced closing of $5 million public offering. Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares jumped 17% to $0.1199 in pre-market trading after falling 8% on Thursday. The company recently agreed to divest AVTX-800 series. Blue Water Biotech, Inc. (NASDAQ:BW
Gainers MSP Recovery, Inc. (NASDAQ:LIFW) shares climbed 81.5% to $0.2793 after jumping 64% on Wednesday. Near Intelligence, Inc. (NASDAQ:NIR) gained 52.5% to $0.3188. Near Intelligence said it is a trusted partner of leading global commercial real estate companies seeking high-quality real estate analytics on any location, building or site. Murphy Canyon Acquisition Corp. (NASDAQ:MURF) shares gained 40.9% to $18.09. Murphy Canyon Acquisition reported stockholder approval of the proposed combination with Conduit Pharmaceuticals. TradeUP Acquisition Corp. (NASDAQ:UPTD) shares climbed 35.8% to $16.63 after surging 26% on Wednesday. The company announced an extension for its initial busin
Applied Molecular Transport Inc (NASDAQ:AMTI) has agreed to merge with Cyclo Therapeutics Inc (NASDAQ:CYTH) in an all-stock transaction. Following the merger's closing, the combined company will operate under Cyclo Therapeutics and continue trading on The Nasdaq Capital Market under the CYTH ticker. The combined company will focus on advancing Cyclo Therapeutics' pivotal Phase 3 global study (TransportNPC) evaluating Trappsol Cyclo for Niemann-Pick Disease Type C1. The transaction is expected to close in the fourth quarter of 2023. Under the terms of the Merger Agreement, AMT stockholders will receive approximately 0.174 shares of Cyclo Therapeutics in exchange for each of their shares i
– Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in patients receiving placebo plus adalimumab at week 8 – Post hoc analysis of patients with shorter duration of ulcerative colitis (UC) < 5 years showed clinical remission rate of 43.8% (7/16) in patients receiving combination versus 15.4% (2/13) in patients receiving adalimumab alone, suggesting combination treatment earlier in the course of disease may be beneficial – AMT-101 appeared safe and well-tolerated – Company will host live conference call and webcast today, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT) SOUTH SAN FRANCISCO, Calif., July 06
SOUTH SAN FRANCISCO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selective, oral fusion of IL-10) with anti-TNFα in biologic-naïve patients with moderate-to-severe ulcerative colitis. The company will issue a premarket press release and host a live webcasted conference call on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT). Conference Call & Webcast InformationTo join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and
– Met pre-specified efficacy endpoints in chronic pouchitis, a difficult-to-treat inflammatory bowel disease (IBD)– AMT-101 demonstrated favorable clinical activity and appeared safe and well-tolerated, supporting potentially best-in-class profile– Achieved clinically meaningful responses in stool frequency and histologic healing in both 3mg and 10mg dosage groups– Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 in chronic pouchitis– Further substantiates potential of AMT-101 and Company's oral biologics platform– Investor conference call and webcast today at 8:30 a.m. ET (5:30 a.m. PT) SOUTH SAN FRANCISCO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Appli
- Live Conference Call and Webcast on Monday, April 25, 2022, at 8:30 a.m. ET (5:30 a.m. PT) SOUTH SAN FRANCISCO, Calif., April 24, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 FILLMORE monotherapy trial for AMT-101 (GI- selective, oral fusion of IL-10) in patients with chronic pouchitis in a premarket press release and webcasted conference call on Monday, April 25, 2022, at 8:30 a.m. ET (5:30 a.m. PT). Conference Call & Webcast InformationTo participate in the conference call, please dial (844) 422-9742 (Domestic) or (706) 758-6032 (International) and refer to con